Xiaohong Niu

Evaluation of health-related quality of life using EQ-5D in China during the COVID-19 pandemic

Weiwei Ping, Jianzhong Zheng, Xiaohong Niu et al. · PLoS ONE · 2020 · 288 citations · Full text

Pharmacy, Health Sciences, Behavioral Health +16

<p>Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes</p>

Xiao‐Han Tang, Xiang Yan, Hou‐De Zhou et al. · Diabetes Metabolic Syndrome and Obesity · 2019 · 38 citations · Full text

Medicine, Endocrinology, Internal Medicine +11

Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro

Jingquan Ji, Feng Ming, Yan Huang et al. · Bioengineered · 2022 · 38 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15

Adding vitamin D3 to the dipeptidyl peptidase‐4 inhibitor saxagliptin has the potential to protect β‐cell function in LADA patients: A 1‐year pilot study

Ziwei Zhang, Xiang Yan, Chao Wu et al. · Diabetes/Metabolism Research and Reviews · 2020 · 26 citations

Medicine, Endocrinology, Pharmacotherapy +17

Identification of a distinct phenotype of elderly latent autoimmune diabetes in adults: LADA China Study 8

Xiaohong Niu, Shuoming Luo, Xia Li et al. · Diabetes/Metabolism Research and Reviews · 2018 · 23 citations

Life Sciences, Endocrinology, Immunology +17